Pharmafile Logo
Pharmafocus logo
Advanced Search

daclatasvir

Showing 7 posts of 7 posts found.

bms_logo_square

Europe approves BMS hep C drug for HIV and liver transplant patients

February 1, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, daclatasvir, daklinza

The European Commission has approved the expanded use of Bristol Myers-Squibb’s hepatitis C drug Daklinza (daclatasvir), to include liver transplant …

News
Medicines Patent Pool

BMS and Medicines Patent Pool collaborate to increase Hep C medicine access

November 25, 2015
Manufacturing and Production, Research and Development Bristol-Myers Squibb, Medicines Patent Pool, daclatasvir, daklinza, hepatitis C

The Medicines Patent Pool (MPP) has announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers …

News
Merck image

Conference round-up: companies go big on hepatitis C at EASL

April 29, 2015
Sales and Marketing Bristol-Myers Squibb, EASL, Merck, daclatasvir, daklinza

Big pharma names posted favourable results for hepatitis C treatments as they jostled for position as market leaders at the …

News
BMS image

BMS pulls hep C combo treatment in US

October 7, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Combo, HCV, asunaprevir, daclatasvir, hep C, sovaldi

Bristol-Myers Squibb will not attempt to bring its new combination hepatitis C treatment to the US market given the current …

News
BMS image

CHMP approves six drugs including daclatasvir

June 30, 2014
Sales and Marketing BMS, CHMP, HCV, Plavix, daclatasvir, daklinza, ge

A key advisory committee for the European Medicines Agency has given its approval to six new drugs at its latest …

News
merck_incweb

Merck gets hep C boost as competition ramps up

April 11, 2014
Research and Development, Sales and Marketing Merck, daclatasvir, hep C, sovaldi

Merck has released promising data from a trial which uses two of its investigational compounds to treat patients with hepatitis …

News
BMS image

EMA to review daclatasvir

January 9, 2014
Sales and Marketing BMS, EMA, daclatasvir, hep C

European regulators are to conduct a speedy investigation into one of Bristol-Myers Squibb’s investigational drugs for chronic hepatitis C virus …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025